Edoxaban impurity 1

Catalog No. :
ACCYEZ195
CAS No. :
41374-72-5
Molecular Formula :
C9H10N2O3
Molecular Weight :
194.19

IUPAC Name:ethyl 2-oxo-2-(pyridin-2-ylamino)acetate

Edoxaban impurity 1 structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
25mg95%$103.00Login to see priceInquiryInquiry
50mg95%$158.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameEdoxaban impurity 1
IUPAC Nameethyl 2-oxo-2-(pyridin-2-ylamino)acetate
MDL No.MFCD02317206
Molecular FormulaC9H10N2O3
Molecular Weight194.19
SMILESO=C(OCC)C(NC1=NC=CC=C1)=O
InChI KeyNYZGUHLYCAATGR-UHFFFAOYSA-N
SynonymEdoxaban impurity K;ethyl 2-oxo-2-(2-pyridylamino)acetate;N-Pyridin-2-yl-Oxalamic Acid Ethyl Ester;Ethyl 2-oxo-2-(pyridin-2-ylamino)acetate (Edoxaban Impurity);ethyl[(pyridin-2-yl)carbamoyl]formate;Acetic acid, 2-oxo-2-(2-pyridinylamino)-, ethyl ester;Ethyl 2-oxo-2-(2-pyridinylamino)acetate;Edoxaban Impurity 159
CAS No.41374-72-5

Safety Data

Pictogram
Harmful or irritantHealth hazardEnvironmental hazard
Signal Word
Gefahr
Hazard Statement(s)
H302-H319-H372-H410
Precautionary Statement(s)
P260-P264-P273-P301+P312-P305+P351+P338-P314

Synthetic Route by SureRoute

1. ACCYEZ195 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACKWTD320 route compound structure diagram
    ACKWTD32032654-45-8 In Stock
  4. Then
  5. ACCYEZ195 route product structure diagram
    ACCYEZ19541374-72-5 In Stock
Inquiry

2. ACCYEZ195 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACFBKI731 route compound structure diagram
    ACFBKI731617-37-8 In Stock
  2. Plus
  3. ACKWTD320 route compound structure diagram
    ACKWTD32032654-45-8 In Stock
  4. Then
  5. ACCYEZ195 route product structure diagram
    ACCYEZ19541374-72-5 In Stock
Inquiry

Comments (0)